Literature DB >> 21880578

The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis.

Hiroki Ito1, Ivan V Pacold, Ramon Durazo-Arvizu, Kiang Liu, Michael G Shilipak, David C Goff, Russell P Tracy, Holly Kramer.   

Abstract

The authors studied the incremental value of adding serum cystatin C or creatinine to the Framingham risk score variables (FRSVs) for the prediction of incident cardiovascular disease (CVD) among 6,653 adults without clinical CVD utilizing the Multi-Ethnic Study of Atherosclerosis (2000-2008). CVD events included coronary heart disease, heart failure, stroke, and peripheral arterial disease. Variables were transformed to yield optimal prediction of 6-year CVD events in sex-stratified models with FRSVs alone, FRSVs + cystatin C, and FRSVs + creatinine. Risk prediction in the 3 models was assessed by using the C statistic, and net reclassification improvement was calculated. The mean ages were 61.9 and 64.6 years for individuals with and without diabetes, respectively. After 6 years of follow-up, 447 (7.2%) CVD events occurred. In the total cohort, no significant change in the C statistic was noted with FRSVs + cystatin C and FRSVs + creatinine compared with FRSVs alone, and net reclassification improvement for CVD risk was extremely small and not significant with the addition of cystatin C or creatinine to FRSVs. Similar findings were noted after stratifying by baseline presence of diabetes. In conclusion, the addition of cystatin C or serum creatinine to FRSVs does not improve CVD risk prediction among adults without clinical CVD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880578      PMCID: PMC3218629          DOI: 10.1093/aje/kwr185

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  27 in total

1.  Size matters to a model's fit.

Authors:  James P Marcin; Patrick S Romano
Journal:  Crit Care Med       Date:  2007-09       Impact factor: 7.598

2.  The effect of including C-reactive protein in cardiovascular risk prediction models for women.

Authors:  Nancy R Cook; Julie E Buring; Paul M Ridker
Journal:  Ann Intern Med       Date:  2006-07-04       Impact factor: 25.391

3.  Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Joachim H Ix; Michael G Shlipak; Glenn M Chertow; Mary A Whooley
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

4.  An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.

Authors:  Aaron R Folsom; Lloyd E Chambless; Christie M Ballantyne; Josef Coresh; Gerardo Heiss; Kenneth K Wu; Eric Boerwinkle; Thomas H Mosley; Paul Sorlie; Guoqing Diao; A Richey Sharrett
Journal:  Arch Intern Med       Date:  2006-07-10

5.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  Andrew S Levey; Kai-Uwe Eckardt; Yusuke Tsukamoto; Adeera Levin; Josef Coresh; Jerome Rossert; Dick De Zeeuw; Thomas H Hostetter; Norbert Lameire; Garabed Eknoyan
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

6.  Cystatin C and the risk of death and cardiovascular events among elderly persons.

Authors:  Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen
Journal:  N Engl J Med       Date:  2005-05-19       Impact factor: 91.245

7.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

8.  Assessing the calibration of mortality benchmarks in critical care: The Hosmer-Lemeshow test revisited.

Authors:  Andrew A Kramer; Jack E Zimmerman
Journal:  Crit Care Med       Date:  2007-09       Impact factor: 7.598

9.  Kidney disease, Framingham risk scores, and cardiac and mortality outcomes.

Authors:  Daniel E Weiner; Hocine Tighiouart; John L Griffith; Essam Elsayed; Andrew S Levey; Deeb N Salem; Mark J Sarnak
Journal:  Am J Med       Date:  2007-06       Impact factor: 4.965

Review 10.  Chronic kidney disease: effects on the cardiovascular system.

Authors:  Ernesto L Schiffrin; Mark L Lipman; Johannes F E Mann
Journal:  Circulation       Date:  2007-07-03       Impact factor: 29.690

View more
  12 in total

Review 1.  A systematic review of the status and methodological considerations for estimating risk of first ever stroke in the general population.

Authors:  Wei Xu; Jiuyi Huang; Qingsong Yu; Hongfan Yu; Yang Pu; Qiuling Shi
Journal:  Neurol Sci       Date:  2021-03-30       Impact factor: 3.307

2.  Subclinical atherosclerosis measures for cardiovascular prediction in CKD.

Authors:  Kunihiro Matsushita; Yingying Sang; Shoshana H Ballew; Michael Shlipak; Ronit Katz; Sylvia E Rosas; Carmen A Peralta; Mark Woodward; Holly J Kramer; David R Jacobs; Mark J Sarnak; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

3.  Risk Prediction Models for Atherosclerotic Cardiovascular Disease in Patients with Chronic Kidney Disease: The CRIC Study.

Authors:  Joshua D Bundy; Mahboob Rahman; Kunihiro Matsushita; Byron C Jaeger; Jordana B Cohen; Jing Chen; Rajat Deo; Mirela A Dobre; Harold I Feldman; John Flack; Radhakrishna R Kallem; James P Lash; Stephen Seliger; Tariq Shafi; Shoshana J Weiner; Myles Wolf; Wei Yang; Norrina B Allen; Nisha Bansal; Jiang He
Journal:  J Am Soc Nephrol       Date:  2022-02-10       Impact factor: 10.121

4.  Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study.

Authors:  Kunihiro Matsushita; Yingying Sang; Shoshana H Ballew; Brad C Astor; Ron C Hoogeveen; Scott D Solomon; Christie M Ballantyne; Mark Woodward; Josef Coresh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-29       Impact factor: 8.311

Review 5.  Cardiovascular risk prediction in people with chronic kidney disease.

Authors:  Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-11       Impact factor: 2.894

6.  Serum cystatin C - marker of inflammation and cardiovascular morbidity in chronic kidney disease stages 1-4.

Authors:  Alma Muslimovic; Denijal Tulumovic; Senad Hasanspahic; Aida Hamzic-Mehmedbasic; Ramajana Temimovi
Journal:  Mater Sociomed       Date:  2015-04-05

7.  Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.

Authors:  Kunihiro Matsushita; Josef Coresh; Yingying Sang; John Chalmers; Caroline Fox; Eliseo Guallar; Tazeen Jafar; Simerjot K Jassal; Gijs W D Landman; Paul Muntner; Paul Roderick; Toshimi Sairenchi; Ben Schöttker; Anoop Shankar; Michael Shlipak; Marcello Tonelli; Jonathan Townend; Arjan van Zuilen; Kazumasa Yamagishi; Kentaro Yamashita; Ron Gansevoort; Mark Sarnak; David G Warnock; Mark Woodward; Johan Ärnlöv
Journal:  Lancet Diabetes Endocrinol       Date:  2015-05-28       Impact factor: 32.069

8.  Ghrelin Levels and Decreased Kidney Function in Patients with Early Stages of Chronic Kidney Disease Against the Background of Obesity.

Authors:  Nataliia Vasylivna Gubina; Iryna Hryhorivna Kupnovytska; Vasyl Hryhorovych Mishchuk; Halyna Dmytrivna Markiv
Journal:  J Med Life       Date:  2020 Oct-Dec

9.  Age and association of kidney measures with mortality and end-stage renal disease.

Authors:  Stein I Hallan; Kunihiro Matsushita; Yingying Sang; Bakhtawar K Mahmoodi; Corri Black; Areef Ishani; Nanne Kleefstra; David Naimark; Paul Roderick; Marcello Tonelli; Jack F M Wetzels; Brad C Astor; Ron T Gansevoort; Adeera Levin; Chi-Pang Wen; Josef Coresh
Journal:  JAMA       Date:  2012-12-12       Impact factor: 56.272

10.  Estimated glomerular filtration rate, all-cause mortality and cardiovascular diseases incidence in a low risk population: the MATISS study.

Authors:  Chiara Donfrancesco; Simonetta Palleschi; Luigi Palmieri; Barbara Rossi; Cinzia Lo Noce; Fabio Pannozzo; Belinda Spoto; Giovanni Tripepi; Carmine Zoccali; Simona Giampaoli
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.